Patients with primary APS and patients with secondary APS associated to SLE, have a higher prevalence and a higher level of IgA aCL and IgA anti-β 2GPI, when compared to patients with SLE or other autoimmune diseases and without APS. Here, CD79A is linked to systemic lupus erythematosus.